Neurobehavioral Profiles and Clinical Consequences of MYT1L ‐Related Neurodevelopmental Disorder: Insights From the Brain Gene Registry
- 19 October 2026
- journal article
- Published by Wiley in American Journal of Medical Genetics Part A
Abstract
MYT1L ‐Related Neurodevelopmental Disorder ( MYT1L ‐NDD) is a rare autosomal dominant syndrome characterized by intellectual disability, global developmental delay, autism, and obesity. Despite growing recognition, prospective and systematic clinical phenotyping remains limited. Here, we present an exploratory analysis of data from 25 individuals with MYT1L ‐NDD enrolled in the Brain Gene Registry (BGR), a national platform integrating genetic, neurobehavioral, and clinical data. Neurobehavioral assessments were conducted using the Rapid Neurobehavioral Assessment Protocol (RNAP), including virtual adaptations of the Shipley, Developmental Profile‐4, ASEBA Child Behavior Checklist, and Vineland‐3. Diagnostic and medication data were extracted from structured electronic health records (EHR). MYT1L ‐NDD participants were compared to the broader BGR cohort. MYT1L ‐NDD participants exhibited pronounced impairments in nonverbal cognition and adaptive functioning, particularly in motor tasks, communication, and daily living skills. Behavioral assessments revealed elevated rates of autism symptoms, ADHD symptoms, behavioral conduct problems, oppositional defiance, and anxiety. EHR diagnosis data were available for 10 MYT1L ‐NDD participants. It showed frequent diagnoses of developmental delays, speech and language disorders, intellectual disability, gastrointestinal problems, and obesity. Medication data on five participants indicated common prescription of alpha‐2 adrenergic agonists and laxatives. This study provides the first prospective, multi‐source characterization of MYT1L ‐NDD. Findings expand our understanding of MYT1L ‐NDD phenotypes in a quantitative and systematic manner and support the value of registry‐based approaches for understanding rare neurodevelopmental disorders. Larger, longitudinal, age‐stratified studies are needed to further define MYT1L ‐NDD natural history and inform clinical care.Keywords
Funding Information
- National Institutes of Health (P50HD103525)
- National Institutes of Health (R01MH124808)
- National Institutes of Health (R01NS152315)
- National Institutes of Health (U01TR002764)
- National Institutes of Health (U24HG006834)
This publication has 13 references indexed in Scilit:
- Neurodevelopmental Disorders Among Publicly or Privately Insured Children in the United StatesJAMA Psychiatry, 2022
- MYT1L: A systematic review of genetic variation encompassing schizophrenia and autismAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020
- Nine newly identified individuals refine the phenotype associated with MYT1L mutationsAmerican Journal of Medical Genetics Part A, 2020
- A novel MYT1L mutation in a patient with severe early‐onset obesity and intellectual disabilityAmerican Journal of Medical Genetics Part A, 2018
- Refinement of the critical 2p25.3 deletion region: the role of MYT1L in intellectual disability and obesityGenetics in Medicine, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study dataNature Biotechnology, 2013
- Spatiotemporal expression pattern of Myt/NZF family zinc finger transcription factors during mouse nervous system developmentDevelopmental Dynamics, 2013
- Early-onset obesity and paternal 2pter deletion encompassing the ACP1, TMEM18, and MYT1L genesEuropean Journal of Human Genetics, 2013
- MYT1L is a candidate gene for intellectual disability in patients with 2p25.3 (2pter) deletionsAmerican Journal of Medical Genetics Part A, 2011